Recaticimab is a humanized monoclonal antibody directed against PCSK9. Recaticimab could be used as an add-on to moderate-intensity statin therapy significantly and substantially reduced the LDL-C level. Recaticimab has the potential for the treatment of uncontrolled hypercholesterolaemia.